SV

Sambasivan Viswamohan

Director DIN 06777563
DIN 06777563 First appointment Jan 2014
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Jan 2014
Shareholding value β€’β€’β€’β€’ Premium profile

About Sambasivan Viswamohan

Data last updated:

Sambasivan Viswamohan was a Director at Fortilab Pharma Industries Private Limited (from 2014) and Director at Bekra Pharma India Private Limited (from 2020).

DIN 06777563
First Appointment 31 Jan 2014
Oldest Company Age 12 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director31 Jan 20142014₹46,727 (FY 2020)Strike Off
Bekra Pharma India Private Limited U74999TZ2020PTC035004
Director18 Nov 20202020Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Fortilab Pharma Industries Private Limited
Bekra Pharma India Private Limited
Premium access

Shareholding and investment profile for Sambasivan Viswamohan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sambasivan Viswamohan

Sambasivan Viswamohan was first appointed on 31 Jan 2014 as Director at Fortilab Pharma Industries Private Limited. The most recent appointment on record is 18 Nov 2020 at Bekra Pharma India Private Limited.

Sambasivan Viswamohan held 2 earlier board appointments: Fortilab Pharma Industries Private Limited (Director, from 31 Jan 2014); Bekra Pharma India Private Limited (Director, from 18 Nov 2020).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available